Detail Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-(alpha) and ribavirin combination therapy in patients with chronic hepatitis C virus infection (from Hepatology Research 2011, 41, 30-38) Bibliografi Author: Tatsumi, Tomohide ; Takehara, Tetsuo ; Miyagi, Takuya ; Nakazuru, Shoichi ; Mita, Eiji ; Kanto, Tatsuya ; Hiramatsu, Naoki ; Hayashi, Norio Topik: Chronic hepatitis C; HCV-specific CTL; IFN-g ELISPOT; Peg-IFNa; Ribavirin; Validation ref - 6 Bahasa: (EN )     Penerbit: The Japan Society of Hepatology     Tahun Terbit: 2011     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: tatsumi2010.pdf (582.04KB; 0 download) Abstract Aim: Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTLs) play critical roles in elimination of the HCV-infected hepatocytes. However, the mechanism of HCV elimination by pegylated interferon-a (peg-IFNa) plus ribavirin is not fully understood. We examined HCV-specific CTL responses during this combination therapy. Methods: CD8+ T cells were isolated from 16 HCV infected patients treated by this combination therapy and were subjected to IFN-g enzyme-linked immunospot (ELISPOT) assay. Results: The numbers of IFN-g spots against HCV Core or NS3 protein-derived peptides in HCV patients before treatment were similar to those in healthy donors, and those in HCV patients significantly increased 4 weeks after the initiation of combination therapy. All HCV Core or NS3 proteins-derived peptides specific CD8+ T cells responses in pre-treated patients were not associated with ALT levels and HCV viral loads of HCV patients before treatment. And those in pre-treated patients were similar between sustained virologic responder (SVR) patients and non-SVR patients. Significant increase of HCV Core or NS3 proteins-derived peptides specific CD8+ T cells responses between before and 4 weeks after this combination therapy were observed in SVR patients, but not in non-SVR patients. Conclusions: These results demonstrated that significant increase of HCV-specific CD8+ T cells at 4 weeks after the initiation of IFN treatment might be associated with the elimination of HCV. Our findings suggest that the reactivity against HCV Core and NS3 proteins-derived peptides might be useful in predicting the clinical outcome of the combination therapy of peg-IFNa and ribavirin. [validation ref - 6] Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved